J&J Reportedly in Talks to Buy Protagonist

J&J reportedly in talks to buy Protagonist

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. My colleagues were hard at work throughout the weekend reporting on major firings across the CDC. We’ve also got a ton of biopharma news to catch up on below. The need-to-know this morning Biocryst Pharmaceuticals is acquiring Astria Therapeutics in a cash-and-stock deal with a $700 million enterprise value. …

J&J in talks to acquire Protagonist Therapeutics

Johnson & Johnson (J&J) is in discussions to purchase Protagonist Therapeutics, as reported by The Wall Street Journal.